Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 14, Issue 12, 1999, Pages 2907-2914

  Chertow, Glenn M ^a,d   Burke, Steven K ^b   Dillon, Maureen A ^b   Slatopolsky, Eduardo ^c  

^a UCSF Medical Center at Parnassus   (United States)

^b GENZYME CORPORATION   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcium; Cholesterol; End stage renal disease; Haemodialysis; Hyperparathyroidism; Hyperphosphataemia; Phosphate

Indexed keywords

CALCIUM ION; CALCIUM PHOSPHATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYDROGEL; INFECTION; KIDNEY FAILURE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032759970     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.12.2907     Document Type: Article

References (28)

1. Slatopolsky E, Lopez-Hilker, Delmez J, Dusso A, Brown A, Martin KJ. The parathyroid-calcitriol axis in health and chronic renal failure. Kidney Int Suppl 1990; 29: S41-S47
2. Gonzalez EA, Martin KJ. Renal osteodystrophy: pathogenesis and management. Nephrol Dial Transplant 1995; 3: 13-21
3. Piraino B, Chen T, Cooperstein L, Segre G, Puschett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 1988; 30: 57-62
4. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoetin in uremia. N Engl J Med 1993; 328: 171-175
5. Massry SG, Goldstein DA. Role of parathyroid hormone in uremic toxicity. Kidney Int Suppl 1978; 8: S39-S42
6. Bogicevic M, Stefanovic V. Relationship between parathyroid hormone and pituitary-testicular axis in patients on maintenance hemodialysis. Exp Clin Endocrinol 1988; 92: 357-362
7. Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997; 30: 606-620
8. Fliser D, Franek E, Fode P, Stefanski A, Schmitt CP, Lyons M, Ritz E. Subacute infusion of physiologic doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997; 12: 933-938
9. Nishizawa Y, Shoji T, Kawagishi T, Morii H. Atheroslcerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int Suppl 1997; 62; S90-S92
10. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ. Phosphorus restriction prevents parathyroid gland growth: High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534-2540
11. Goodman WG. Bone disease and aluminum: pathogenic considerations. Am J Kidney Dis 1985; 6: 330-335
12. Drucke TB, Lacour B, Touam M, Jacquel JP, Plachot JJ, Cournot-Witmer G, Galle P. Effect of aluminum on hematopoesis. Kidney Int Suppl 1986; 18: S45-S48
13. Arieff AI. Aluminum and the pathogenesis of dialysis encephalopathy. Am J Kidney Dis 1985; 6: 317-321
14. Slatopolsky EA, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez JA. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315: 157-161
15. Mai ML, Emmet M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS. Calcium acetate, and effective phosphorus binder in patients with renal failure. Kidney Int 1989; 36: 690-695
16. Meric F, Yap P, Bia MJ. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 1990; 16: 459-464
17. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E. Poly[allylamine hydrochloride] (RenaGel): a non-calcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71
18. Bleyer AJ, Garrett B, Kant KS, Lynch D, Rahman N, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E. An open-label, cross-over study of the new phosphate binder RenaGel in the management of hyperphosphatemia in ESRD patients. Am J Kidney Dis 1999; 33: 694-701
19. Chertow GM, Dillon M, Burke SK et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium: strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999; 51: 18-26
20. Molgaard H, von Schenck H, Olsson AG. Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolemia. Eur J Clin Pharmacol 1989; 36: 455-460
21. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364
22. Probstfield JL, Statland BE, Gorman L, Hunninghake DB. Alterations in human serum alkaline phosphatase and its isoenzymes by hypolipidemia agents: colestipol and clofibrate. Metabolism 1983; 818-821
23. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
24. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458-482
25. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54: 627-636
26. Ma KW, Greene EL, Raji L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992; 19: 505-513
27. Tschope W, Koch M, Thomas B, Ritz E, and the German Study Group Diabetes and Uremia. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Nephron 1993; 64: 354-358
28. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805